Historians have long recognized that medical prognosis, along with diagnosis and treatment, constitute the backbone of clinical medicine. 
Peter Keating and Alberto Cambrosio compounded by the fact that even when an individual prognosis is made, it cannot, except by definition, be easily detached from the biology of the individual or the natural history of disease. Indeed, practitioners readily admit that " [t] he two fundamental processes in medicine, those of diagnosis and prognosis, are confused at times".5 As can be easily imagined, any diagnosis produces some kind of prognosis if only that of "future uncertain".
The intertwining of diagnosis and prognosis can be explored in many ways. No matter how this is done, however, it must be admitted that the post-war rise of that novel epistemological, social and institutional fusion ofbiology and pathology known as biomedicine provides the context within which these evolving relations must first be examined.6 In this paper we explore the evolution of relationships between clinical or prognostic classifications and those (mainly diagnostic) developed in adjacent areas of biomedicine such as pathology and histology. We focus in particular on the continuing attempts since the Second World War to relate clinical research findings to biological and pathological findings and to develop standards that allow clinical researchers to compare across clinical trials. Despite constant pressure from both biology and pathology to align classifications with these external, and therefore, more "objective" standards, clinical research has attempted to maintain its own criteria of relevance and success in the constant revision of its norms and forms. None the less, clinical classifications have become increasingly based on biological and pathological findings. Indeed, partly due to the increasing role played by multi-centre, co-operative clinical trials in modern cancer therapy, independent "prognostic" classifications have emerged to organize, collate and standardize forms of information formerly contained within diagnostic categories.
Such tensions may seem obvious from a pragmatic point ofview. In addition to connecting individual patients to larger biological and pathological categories, clinical classifications that "stage" tumours according to their anatomic extent or spread, or that "grade" tumours according to their aggressivity depending upon their histological appearance at biopsy, determine therapeutic choices. In this sense, the purpose of clinical classifications clearly goes beyond the mere articulation ofthe "art" oftherapy with the more fundamental "scientific" categories of pathology and biology. It is equally obvious, however, that an efficient and useful staging system is not necessarily very enlightening with regards to the pathological mechanisms underlying the emergence and spread of the disease in question. Similarly, the classification of diseases according to their histopathology may not be the most adequate reflection of the molecular-biological entities at play in the process. Finally, ordering pathological entities according to their biological substratum or constituents may contribute little to their immediate clinical management. In short, there are a number of problems attendant upon the articulation and confrontation of the various kinds of classifications.
As an illustration of these remarks, we have chosen to examine the evolution of clinical and histopathological classifications of the lymphomas. This category includes two distinct yet related classes of disease: Hodgkin's disease and the non-Hodgkin's lymphomas. These two classes allow us to develop a comparison and show that, for example, whereas clinical staging emerged ahead of and in some respects outside of biological and pathological 5Mary Gospodarowicz et al., 'Prognostic factors in 6For a description of biomedicine and its specific clinical decision making: the future', Cancer, 2001 , 91: epistemic and institutional contours, see Peter Keating 1688 -95, p. 1688 . and Alberto Cambrosio, 'Biomedical platforms', Configurations, 2000 Diagnosis, Prognosis and Classification of Lymphomas theories of the spread of the disease in the case of Hodgkin's disease, attempts to develop a similar staging system for the lymphomas were not so successful. Given that work continues within this enterprise, our remarks should be considered more exploratory than definitive. We can none the less state at the outset that it is not so much that diagnosis and prognosis are confused, as that: (1) many classifications of the same entity or person are possible depending upon the purpose of the classification, and (2) a single classification may contain both diagnostic and prognostic dimensions. In other words, it seems that classifications respond to multiple agendas.7 Consider, for example, the following case of an individual diagnosed with nonHodgkin's lymphoma (NHL):
I was diagnosed April 1, 1996. I had a swollen neck gland and the back of my tongue had a huge hump on it. The ear, nose and throat doctor took a piece off the back of my tongue, sent me over for X-rays and a CT scan (both negative by the way). I went back to the ENT doctor in two days and he gave me the bad news: large B-cell NHL, diffuse. I then went to an oncologist friend who I had known-for twenty-five years, though not professionally. He did bone marrow studies, a spinal fluid analysis, more CT scans, all kinds of blood work and put me to sleep for a gastroenterology looksee ... all negative, so he staged it HA, high grade.... After seven CHOP [chemotherapeutic] treatments, I had radiation to the neck area every day for four weeks. I was left with very painful yet numb feet, and tingling in my left arm, which is still there.8 This initial diagnosis contained, in spite ofits neutral presentation as a scientific observation, a form of prognosis, which the patient termed "bad news". As we will see, specification of the lymphoma as "large B-cell NHL, diffuse" already says a lot about what is expected to happen to the patient and what is expected to happen to the disease. Secondly, when such a category of disease is "staged" as in "HA, high grade", more than prognosis-for these are indeed prognostic terms-is at stake. In order to reach such a conclusion, clinicians and laboratory investigators necessarily undertook an exploration of the biology of the entity in question-described, for example, its targets and its spread-thus further specifying the diagnosis. As in the world of Laplacian physics, a complete diagnosis would result in an exact prognosis just as an exact prognosis would presuppose a complete diagnosis.
In what follows, our discussion will include both Hodgkin's disease and non-Hodgkin's lymphomas in recognition of the fact that there has been a continual evolution in the relation between the lymphomas and the disease first described by Thomas Hodgkin in 1832. Although the name "non-Hodgkin's lymphomas" seems to suggest that Hodgkin's disease is a lymphoma, the two have been treated both clinically and pathologically quite separately since the end of the Second World War. Their divergent evolution allows us the opportunity to make a number of comparative remarks concerning the complex relations that exist between prognostic and diagnostic classifications, and the manifold ways in which biomedical innovation may transform these relations.
Since the beginning of the twentieth century, Hodgkin's disease has been defined as a discrete histopathological entity on the basis of the presence of a giant cell known as the Arzneim-Forsch./ Drug Res., 1987, 37: 255-9. 10A committee of experts, many of whom had been involved in the formulation of the 1994 REAL classification, working for the WHO recently failed to reach a conclusion on this score. Pathologists on the committee felt that the term Hodgkin's disease should be abandoned in favour of Hodgkin's lymphoma. Other members of the committee felt the change "unnecessary". See London, Heinemann Educational, 1963, pp. 629-47 . In the seventeenth century and the revival of clinical description, the anatomo-clinical Diagnosis, Prognosis and Classification of Lymphomas the term "treated history" over "natural history".'2 Prognosis, in other words, has been separated from diagnosis even though, as previously noted, knowledge of one generally entails knowledge of the other.
The most widespread of the aforementioned staging schemes in the field of cancer is the TNM (tumour, node, metastasis) system. Although, for anatomical reasons, the TNM system cannot be used to stage lymphomas, its extra-clinical origin does bear mention. Not originally intended to direct treatment management, the TNM system grew out of French wartime efforts to develop a nomenclature for a public health enterprise known as the Permanent Cancer Survey. Organized by the National Hygiene Institute, the Survey set out in 1943 to create a cancer register, including all cases of the disease treated in cancer centres. Initial results showed, however, that uniform categorization of the cancers was consistently compromised by the fact that the same "histological" cancer could be registered under a variety of names depending upon the anatomical extent of the disease. 
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Craver's classes24 by evaluating her population of patients treated at the Toronto General in terms of the factors that correlated with five-and ten-year survival rates. The most significant prognostic factors turned out to be extent of anatomical involvement upon presentation of disease or, in other words, Craver's classes. Unlike the latter, however, Peters' articulation of the classes with survival data enabled her to specify three stages based not only on presentation ofthe anatomic extent of disease, but also on response to treatment. For example, Peters defined stage one as more than "involvement of only one lymph node region or a single lesion elsewhere, with no constitutional symptoms"; indeed, she went on to show that the five-year survival rate following radiotherapy was approximately 88 per cent. Unlike the classes, then, the stages were correlated with treatment history and could thus be construed as "truly" prognostic.
The stages thus overlapped with but were not identical to the clinical pictures or classes. In particular, Peters went on in the same paper to use the stages in a comparison oftwo forms of irradiation therapy; one with and one without prophylactic radiation. In other words, Peters made uniform therapy possible-impossible, we recall, according to Gilbert-by dividing the disease into stages and putting patients into the stages rather than drawing increasingly complicated "forms" in an attempt to gather patients into a complex series of "pictures" .25 More than a description, stages set out prescriptions or rules for therapeutic intervention.
An additional consequence of Peter's scheme was that, by reporting treatment results in terms of clinical classification, she described the evolution of the disease under specific therapeutic regimes; a "treatment history" as opposed to a "natural history". Peters' approach not only constituted a decisive step in the standardization of treatment but also overcame the initial obstacle to that standardization, the cloudy picture presented by the somewhat fluid pathology. Peters' scheme also showed the "clinical" classification to be superior to the "pathological" classification in terms of prognosis. In particular, she concluded as a result of her findings that "the pathological picture is a very necessary, indeed the only proof of the diagnosis, but in establishing the prognosis it acts as a valuable aid, but is not as conclusive as the clinical factors" . ', Nouv. Rev. Fr. Hematol., 1966, 6: 6-120. 32Robert J Lukes, C Gompel, and C Nezelof, 'Le diagnostique histopathologique de la maladie de Hodgkin. Analyse preliminaire d'une etude conduite a l'aveugle sur 395 observations par trois pathologistes de nationalite differente ', Nouv. Rev. Fr. Hematol., 1966,6: 11-15, p. 14. Lukes presented his system using 377 cases from the Armed Forces Institute of Pathology Collection. See R J Lukes, J Butler, and Ethel B Hicks, 'Le pronostic de la maladie de Hodgkin d'apres la variete histologique et le stade clinique ', Nouv. Rev. Fr. Hematol., 1966, 6: 15-22 . 33 The modification consisted of the addition of a stage four proposed by Kaplan in 1963. The stages were further sub-coded "A" (asymptomatic) or "B" (symptomatic: fever, night sweats and itching). The Although it continued the themes at the Paris conference, the Rye symposium also occurred within a framework of conferences that had been set up by the American Cancer Society (ACS) Diagnosis, Prognosis and Classification of Lymphomas the appearance of multiple theories of the spread of Hodgkin's did nothing to diminish the utility of Peters' stages. All clinical trials continued to use the stages as a starting point. The stages were, in other words, relatively invulnerable to changes in biology and pathology. The theories of the spread of Hodgkin's were not, of course, useless. As a recent editorial concerning the spread of Hodgkin's recognized, regardless of the exact nature of a "correct" theory, Kaplan and Rosenberg's "hypothesis" "constituted the rationale to undertake large prophylactic irradiation" and continues to have relevance today.55 The relative autonomy of the Hodgkin's staging system, first codified in Paris and Rye, was reaffirmed in subsequent reforms known as the Ann Arbor (1971) and Cotswolds (1979) reforms.56 No such elucidation occurred with the non-Hodgkin's lymphomas. Briefly, the staging system that worked so well in Hodgkin's provided relatively little prognostic information in the case of the lymphomas. Clinical researchers consequently turned to the histopathological classification for guidance. Here, however, the immunological revolution of the early 1970s undermined the biological basis of the histology leading to a series of reforms that, in the end, forced clinicians to accept a classification that made no pretence of prognosis and that was, in fact, openly hostile to such attempts.
Non-Hodgkin's Lymphomas and the Confrontation of Biology and Pathology
Until the advent of combination chemotherapy in the late 1960s, the treatment of nonHodgkin's lymphomas, like that of Hodgkin's, consisted mainly of radiation. As with Hodgkin's disease, the tumour, node, metastasis staging (TNM) was not appropriate. In the case of the lymphomas, this was in part because there is no way to determine the site of origin of the disease. Consequently, it is impossible to distinguish between the three elements of the TNM system.57 Most radiotherapists had, by then, adopted Peters' and later the Rye staging system for the NHLs, in part because they treated both Hodgkin's and the NHLs. The National Cancer Institute Radiation Branch, for example, had adopted Peters' Archives, 1977. 72Army Institute of Pathology, Annual Report, 1972, p. 116. As the director of the Atlas of Tumor Pathology noted at the time: "As I understand it, it has always been customary to print about 5,000 to 6,000 copies of each fascicle and then when the supply runs low to reprint until 15,000 copies have been printed. In the case of Tumors of the Hematopoietic System, the market was so thirsty and the Fascicle so superb that all the copies were gone in about five months". Harlan I Firminger to Henry Rappaport, 23 May 1967, Box 31, Correspondence, Army Institute of Pathology Archives, 1961 Archives, -1967 As head of the Pathology Advisory Committee of the NCI clinical cancer trial groups programme, and in the absence of a staging system for the non-Hodgkin's lymphomas, Lukes needed a "provisional classification and grouping" of the latter in order to organize patients into histopathological diagnostic groups. The 1956 version of Rappaport's system provided just such criteria with the added prognostic bonus. Noting that the system would be "subject to verification on the basis of future experience", Lukes outlined the possible pitfalls of such a bootstrapping operation. The serial correction proposed by the Pathology Advisory Committee-start with simple categories and see what turns up-presupposed that the large categories themselves could be easily filled. As Lukes demonstrated, however, pathologists could be consistently confounded in the diagnosis of lymphomas, notably in confusing the benign with the malignant, the most important prognostic categories of all. Partly because of considerable visual overlap between entities, histopathologic diagnosis was further complicated by the fact that many of the preparations involved manual techniques. In some instances, the only way to ensure consistency of preparation was to institutionalize bias: Lukes' group, for example, employed "one specially trained technician to prepare all the histologic sections".73 Moreover, a team of three pathologists headed by Lukes studied all histology sections prepared for the Southeastern group at the Army Institute of Pathology, reaching diagnosis by consensus. This careful pathology was only a beginning. Thus, Lukes believed that, ultimately, it would be "essential for the pathologists of each study group to collaborate in a comparative study of histologic case material in an attempt to achieve uniform criteria for diagnosis and classification of the lymphomas".74
The large-scale clinical trials for non-Hodgkin's lymphomas that emerged at about the time of the Rye conference further bolstered the value of histologic management and Rappaport's classification. Following the formation of the task forces by the NCI, and in order to ensure uniformity of diagnosis in the lymphomas and thus to ensure comparability of treatment results, the Lymphoma Task Force set up a pathology panel run this time by Rappaport himself. Reporting to the Lymphoma Task Force in 1967, Rappaport noted that the pathology panel served "as a critical reference for the diagnosis and classification of pathologic specimens from patients with lymphomas entered in co-operative group chemotherapy protocols".75 As head of the panel, Rappaport was in a position to mandate his prognostic-histopathologic system for the lymphomas as a progressively widening standard. The fact that the late 1960s had also seen the introduction of a "standard" chemotherapy treatment (CHOP) meant that a growing number of phase two and phase three protocols were needed to extend the original findings (phase one) and compare alternatives to the standard (phase three). Semin. Hematol., 1978, 15: 322-51 , and R J Lukes et al., 'A morphologic and immunologic surface marker study of 299 cases of non-Hodgkin lymphomas and related leukemias', Am. J. Pathol., 1978, 90: 461-85 differing prognoses and that having reworked their own data, proposed to others that "Morphologic subclassification of diffuse 'histiocytic' lymphoma may be useful in predicting response to chemotherapy and survival". J A Strauchen et al., 'Clinical relevance of the histopathological subclassification of diffuse "histiocytic" lymphoma', N. Engl. J. Med., 1978 Med., , 299: 1382 Med., -7, p. 1382 . Indeed, as explicitly stated by an international panel of experts set up in the early 1980s by the NCI to study the problem, The Non-Hodgkin's Lymphoma Classification project: "One of the most controversial aspects of the Rappaport classification concerns the group of tumors included within 'diffuse histiocytic lymphoma'. The term 'histiocytic' is now known to be, in some instances, scientifically incorrect. The large cells found in these neoplasms are in most cases derived from lymphocytes, while lymphomas of true histiocytic nature are rare." The Non-Hodgkin's Lymphoma Pathologic Classification Project, op. cit., note 63 above, p. 2120. 83 B N Nathwani et al., ' The clinical significance of the morphological subdivision of diffuse "histiocytic" lymphoma: a study of 162 patients treated by the Southwest Oncology Group', Blood, 1982 , 60: 1068 -74, p. 1068 Committee noted in its report that the key issue was "to discriminate between disease entities and prognosticfactors" (emphasis added).'08 The alliance between prognosis and diagnosis created by Rappaport had come to be viewed more as a problem than a solution.
Conclusion
We have seen that with the rise of clinical research and clinical cancer trials, and the subsequent transformation of natural histories into treated histories, prognosis has emerged as a going concern for clinical researchers conducting clinical trials. Here, the emphasis was not on prognosis as advice one would give to a patient as was the case prior to the Second World War, but as a measure of therapeutic efficacy and as an indicator of the biological reactivity of the different species and subspecies of a particular class of entities to a therapeutic regime. By focusing on populations rather than on individuals, prognosis and prognostic information acquired as much a research value as a clinical value and, in consequence, created a class of consumer that was not restricted to the ill: the clinical researcher. In other words, as suggested at the beginning of this paper, the post-war rise of biomedicine resulted in a new configuration of medical practices. Formerly tied to the doctor-patient relationship, prognosis, now the object of widespread clinical trials and clinical research, has acquired a new epistemic and institutional meaning as a research device. At the same time, in the field of the lymphomas, in keeping with the tendency to analyse morbid entities and processes in biological terms, pathologists have sought to extract "natural history" from "treated history" by disentangling diagnosis and prognosis.
This process was contingent in nature. Whereas radiotherapists transformed the natural history ofHodgkin's disease and led investigations in the biology of its spread, chemotherapists had relatively less impact on the understanding of the lymphomas. Change here originated at the biological pole of the biomedical spectrum, when understanding of the immune system was profoundly changed in the late 1960s and early 1970s. As we have shown elsewhere, however, these changes in themselves were partly prompted by investigations in pathology.109 Clinical pathologists and chemotherapists subsequently followed the specific disease entity that we are treating? Changes in biology necessarily change the description of disease entities and thus impact much more directly upon patient prognosis. In this sense, biomedicine is a two-way street.
